{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:28:48Z","timestamp":1760189328388},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Behcet\u2019s disease is a chronic multi-system disorder of unknown etiology with protean manifestations. Venous thromboembolism is more common than arterial thrombosis, with deep vein thrombosis being the most frequent. Endothelial dysfunction resulting from vascular inflammation is considered to be an important factor of thrombosis, although the endothelial injury itself cannot completely explain the hypercoagulable state of the disease because other vasculitis syndromes do not increase the risk of thrombosis. The aim of this study is to evaluate the prevalence of activated protein C resistance (APC-R) in Egyptian patients with Behcet\u2019s disease. Also, to detect hyperhomocysteinemia in selected cases (with vascular complications) to assess their relationship with thromboembolic complications. The APC resistance ratio mean in the group of patients with vascular involvement was 2.6\u2009\u00b1\u20090.8 which was less than the group with no vascular involvement 2.8\u2009\u00b1\u20090.6, with non- significant P-value (0.5). There was more incidence of ocular lesions in the group of patients with high homocysteine level than the group of patients with normal homocytsteine level with significant P-value (0.08).<\/jats:p>","DOI":"10.1186\/1477-9560-11-17","type":"journal-article","created":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T08:14:29Z","timestamp":1378109669000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Activated protein C resistance in Behcet\u2019s disease"],"prefix":"10.1186","volume":"11","author":[{"given":"Hoda","family":"Abdel Badaee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Edrees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maher","family":"El Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaafar","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,2]]},"reference":[{"key":"191_CR1","first-page":"402","volume":"19","author":"Y Koc","year":"1992","unstructured":"Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, et al.: Vascular involvement in Behcet\u2019s disease. J Rheumatol 1992, 19: 402-410.","journal-title":"J Rheumatol"},{"issue":"12","key":"191_CR2","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/rheumatology\/38.12.1298","volume":"38","author":"A G\u00fcl","year":"1999","unstructured":"G\u00fcl A, Aslantas AB, Tekinay T, Koni\u00e7e M, Oz\u00e7elik T: Procoagulant mutations and venous thrombosis in Beh\u00e7et\u2019s disease. Rheumatology 1999, 38(12):1298-1299.","journal-title":"Rheumatology"},{"key":"191_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0049-3848(02)00085-3","volume":"106","author":"YJ Lee","year":"2002","unstructured":"Lee YJ, Kang SW, Yang JI, Choi YM, Sheen D, Lee EB, Choi SW, Song YW: Coagulation parameters and plasma total homocysteine levels in Behcet\u2019s disease. Thromb Res 2002, 106: 19-24.","journal-title":"Thromb Res"},{"issue":"5","key":"191_CR4","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1136\/ard.43.5.746","volume":"43","author":"RG Hull","year":"1984","unstructured":"Hull RG, Harris EN, Gharavi AE, Tincani A, Asherson RA, Valesini G, Denman AM, Froude G, Hughes GR: Anticardiolipin antibodies: occurrence in Beh\u00e7et\u2019s syndrome. Ann Rheum Dis 1984, 43(5):746-748.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"191_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0038-1648128","volume":"67","author":"O Chafa","year":"1992","unstructured":"Chafa O, Fischer AM, Meriane F, Chellali T, Sternberg C, Otmani F, Benabadji M: Beh\u00e7et\u2019s syndrome associated with protein S deficiency. Thrombosis and Hemostasis 1992, 67(1):1-3.","journal-title":"Thrombosis and Hemostasis"},{"issue":"3","key":"191_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0049-3848(97)00063-7","volume":"86","author":"S Guermazi","year":"1997","unstructured":"Guermazi S, Hamza M, Dellagi K: Protein S deficiency and antibodies to protein S in patients with Behcet\u2019s disease. Thromb Res 1997, 86(3):197-204.","journal-title":"Thromb Res"},{"issue":"4","key":"191_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jbspin.2010.02.022","volume":"77","author":"P Caramaschi","year":"2010","unstructured":"Caramaschi P, Poli G, Bonora A, Volpe A, Tinazzi I, Pieropan S, Bambara LM, Biasi D: A study on thrombophilic factors in Italian Behcet's patients. Joint Bone Spine 2010, 77(4):330-334.","journal-title":"Joint Bone Spine"},{"key":"191_CR8","first-page":"2404","volume":"26","author":"R Mader","year":"1999","unstructured":"Mader R, Ziv M, Adawi M, Mader R, Lavia I: Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet\u2019s disease. J Rheumatol 1999, 26: 2404-2408.","journal-title":"J Rheumatol"},{"key":"191_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1046\/j.1365-4362.1998.00114.x","volume":"37","author":"N Lenk","year":"1998","unstructured":"Lenk N, Ozet G, Alli N, Coban O, Erbasi S: Protein C and protein S activities in Behcet\u2019s disease as a risk factors of thrombosis. Int J Dermatol 1998, 37: 124-125.","journal-title":"Int J Dermatol"},{"key":"191_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0002-9343(01)01048-8","volume":"112","author":"G Espinosa","year":"2002","unstructured":"Espinosa G, Font J, T\u00e0ssies D, Vidaller A, Deulofeu R, L\u00f3pez-Soto A, Cervera R, Ordinas A, Ingelmo M, Reverter JC: Vascular involvement in Beh\u00e7et\u2019s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002, 112: 37-43.","journal-title":"Am J Med"},{"key":"191_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jdermsci.2006.11.008","volume":"45","author":"T Sarican","year":"2007","unstructured":"Sarican T, Ayabakan H, Turkmen S, et al.: Homocysteine: an activity marker in Behcet\u2019s disease. J Dermatol Sci 2007, 45: 121-126.","journal-title":"J Dermatol Sci"},{"key":"191_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1515\/CCLM.2007.018","volume":"45","author":"Y Ozkan","year":"2007","unstructured":"Ozkan Y, Yardim-Akaydin S, Sepici A, et al.: Assessment of homocysteine and nitric oxide levels in Behcet\u2019s disease. Clin Chem Lab Med 2007, 45: 73-77.","journal-title":"Clin Chem Lab Med"},{"issue":"8697","key":"191_CR13","first-page":"1078","volume":"335","author":"International Study Group Criteria","year":"1990","unstructured":"International Study Group Criteria: Lancet. 1990, 335(8697):1078-1080.","journal-title":"Lancet"},{"issue":"2","key":"191_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/00001721-200302000-00001","volume":"14","author":"A Gurgey","year":"2003","unstructured":"Gurgey A, Balta G, Boyvat A: Factor V Leiden mutation and PAI-1 gene 4G\/5G genotype in thrombotic patients with Behcet\u2019s disease. Blood Coagul Fibrinolysis 2003, 14(2):121-124.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"191_CR15","first-page":"2196","volume":"24","author":"L Mammo","year":"1997","unstructured":"Mammo L, Al-Dalaan A, Bahabri SS, Saour JN: Association of factor V Leiden with Behcet\u2019s disease. J Rheumatol 1997, 24: 2196-2198.","journal-title":"J Rheumatol"},{"issue":"4","key":"191_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1365-2141.2004.05072.x","volume":"126","author":"S Navarro","year":"2004","unstructured":"Navarro S, Ricart JM, Medina P, et al.: Activated protein C levels in Behcet\u2019s disease and risk of venous thrombosis. Br J Haematol 2004, 126(4):550-556.","journal-title":"Br J Haematol"},{"key":"191_CR17","first-page":"2849","volume":"27","author":"PB Toydemir","year":"2002","unstructured":"Toydemir PB, Elhan AH, Tukun A, et al.: Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombogenesis in Behcet\u2019s disease. J Rheumatol 2002, 27: 2849-2854.","journal-title":"J Rheumatol"},{"key":"191_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S0002-9394(99)00184-1","volume":"128","author":"DH Verity","year":"1999","unstructured":"Verity DH, Vaughan RW, Madanat W, et al.: Factor V Leiden mutation is associated with ocular involvement in Behcet\u2019s disease. Am J Ophthalmol 1999, 128: 352-356.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"191_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/art.20237","volume":"51","author":"M Silingardi","year":"2004","unstructured":"Silingardi M, Salvarani C, Boiardi L, et al.: Facror V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet\u2019s disease and deep vein thrombosis. Arthritis Rheum 2004, 51(2):177-183.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"191_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/rheumatology\/40.6.687","volume":"40","author":"K Aksu","year":"2001","unstructured":"Aksu K, Turgan N, Oksel F, et al.: Hyperhomocysteinemia in Behcet\u2019s disease. Rheumatology 2001, 40(6):687-690.","journal-title":"Rheumatology"},{"issue":"11 Suppl","key":"191_CR21","first-page":"931","volume":"4","author":"M Okka","year":"2002","unstructured":"Okka M, Ozt\u00fcrk M, Kockar MC, Bavbek N, Rasier Y, Gunduz K: Plasma homocysteine level and uveitis in Behcet\u2019s disease. Isr Med Assoc J 2002, 4(11 Suppl):931-934.","journal-title":"Isr Med Assoc J"},{"issue":"12","key":"191_CR22","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D, et al.: EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008, 67(12):1656-1662.","journal-title":"Ann Rheum Dis"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-9560-11-17.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:15:17Z","timestamp":1630545317000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/1477-9560-11-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["191"],"URL":"https:\/\/doi.org\/10.1186\/1477-9560-11-17","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,2]]},"assertion":[{"value":"20 March 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"17"}}